Medical Director, Rare Blood Disorders
Novo Nordisk, Inc.
Plainsboro, New Jersey, United States
Adam Wufsus, Medical Director, Rare Blood Disorders, NNI, holds a PhD in chemical engineering and has over a decade of experience in rare hematological disorders across numerous settings. His work spans from basic research, where he has published numerous works on the interplay between biochemical and biophysical properties on thrombosis and hemostasis, to medical affairs, where he has been part of several product launches including Rebinyn and Esperoct. Starting in 2020, Adam began serving and interim medical director and then medical director with a focus on sickle cell disease. In this setting Adam aims to work collaboratively with HCPs, patients, and other stakeholders to drive patient-centricity within Novo Nordisk’s sickle cell development program.
Disclosure information not submitted.
Novo Nordisk in Sickle Cell Disease
Friday, June 16, 2023
4:15 PM – 4:25 PM East Coast USA Time
Friday, June 16, 2023
5:15 PM – 5:30 PM East Coast USA Time
Priority Needs of the US Sickle Cell Community: Insights From US Advisory Boards
Sunday, June 18, 2023
1:45 PM – 2:00 PM East Coast USA Time